Clinical Trial Authorisation application granted for combined drug PK051 targeting amyloid deposits associated with Alzheimer’s Disease.
Sunstone Therapies Celebrates Three Year Anniversary With More Than 100 Psychedelic-Assisted Therapy Treatments Completed | Psychedelic Invest
Sunstone Therapies, a leader in the delivery of psychedelic-assisted therapy in the medical setting and the development of clinical trials, announces it has completed more